US Valentis announced that its wholly-owned subsidiary, PolyMASC
Pharmaceuticals, has received a favourable ruling from the Japanese
Patent Office in regard to patent invalidation proceedings brought
by ALZA Corporation, a unit of...
Canadian drug development company Ecopia BioSciences on Monday
announced that it had filed patent applications for the first two
novel compounds using its proprietary drug discovery platform -
suggesting investments by the company...
AAC Consulting Group, the regulatory consulting subsidiary of
contract research organisation Kendle International, has signed an
agreement with two toxicologists to further expand its services to
the food and dietary supplement industries.
As in-licensing opportunities are reduced and competition for
market share in Japan increases with the rising penetration of
western pharma companies, domestic mid-cap players must alter their
strategies to remain independent, writes...
London zoo was the setting last week for UK inspection body Select
QA to formally receive certification from the United Kingdom
Accreditation Service, involving the company in a new scheme for
the food packaging industry.
Alcan Pharma Center, a US division of flexible packaging unit Alcan
Packaging, has installed a new four colour Rotomec 3000-5 ES
gravure printing press, with in-line coating from UK company Valmet
US company Molecular Devices, a supplier of bioanalytical
measurement systems, announced its revenues and earnings for the
quarter and year ended 31 December, 2002. Revenues for the fourth
quarter of 2002 were a healthy $30.2 million,...
Emerson Process Management has received a multi-year contract from
Voridian, a division of Eastman Chemical, to upgrade automation
systems at Voridian's polyethylene terephthalate (PET) polymers
plants in Columbia and in Cosoleacaque,...
German chemicals company Degussa has sold its Frankfurt/Main-based
biopharmaceutical company Zentaris to Canadian firm AEterna
Laboratories for approximately €50 million, the company said last
week. The move marks the much-talked...